China Recombinant Human Interferon a2b Market Investigation Report 2019: Shanghai Huaxin High Biotechnology, Zhaoke Pharmaceutical and Schering-Plough are the Top Players by Sales Value
DUBLIN, Jan. 18, 2019 /PRNewswire/ --
The "Investigation Report on China's Recombinant Human Interferon a2b Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
According to market research, the sales value of Recombinant Human Interferon a2b showed an upward trend after the drug was launched in China, reaching about CNY 271 million in 2017. The injections, capsules and gels take up a large market share, with Shanghai Huaxin High Biotechnology Inc., Zhaoke Pharmaceutical (Hefei) Co. Ltd. and Schering-Plough as the top market players by sales value.
In 1986, Intron A, the world's first Recombinant Human Interferon a2b, was launched by Schering Plough that was later acquired by MSD, and approved by the FDA to be used for the treatment of chronic hepatitis B. In 1997, Tianjin Sinobioway Biomedicine Co., Ltd.'s Recombinant Human Interferon a2b was approved to be sold in China, followed by the counterparts of Anhui Anke Biotechnology (Group) Co., Ltd., Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd. and Schering-Plough that was approved in 1998, 1999 and 2007 respectively.
Recombinant Human Interferon a2b has been approved by the China Food and Drug Administration to be sold in the dosage forms of freeze-dried powder injection, injection, suppository, cream (ointment), eye drops, etc. The main indications include acute and chronic viral hepatitis infections (hepatitis B and hepatitis C), condyloma acuminatum, hairy cell leukemia, etc. and vary among dosage forms.
The researcher estimates that by the end of 2018, more than 90 million people in China were infected with hepatitis B virus and 8 million carried hepatitis C virus. With the increasing incidence of herpes, 80%-90% of the Chinese population are infected with herpes zoster virus, and 30% of the infected may develop chickenpox, and the rest 70% will be attacked by herpes zoster when they are weak. Furthermore, over 40% of married women in China are suffering from cervical erosion.
Key Topics Covered:
1 Relevant Concepts of Recombinant Human Interferon 2b
1.1 Indications for Recombinant Human Interferon 2b
1.2 Development of Recombinant Human Interferon 2b in China
1.3 Governmental Approval of Recombinant Human Interferon 2b in China
2 Sales of Recombinant Human Interferon 2b in China, 2013-2017
2.1 Sales Value of Recombinant Human Interferon 2b
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Interferon 2b
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Interferon 2b by Dosage Form in China, 2013-2017
2.3.1 Sales of Recombinant Human Interferon 2b Gels
2.3.2 Sales of Recombinant Human Interferon 2b Sprays
2.3.3 Sales of Recombinant Human Interferon 2b Suppositories
2.3.4 Sales of Recombinant Human Interferon 2b Injections
2.3.5 Sales of Recombinant Human Interferon 2b Eye Drops
2.3.6 Sales of Recombinant Human Interferon 2b Capsules
2.3.7 Sales of Recombinant Human Interferon 2b Creams (Ointments)
2.3.8 Sales of Recombinant Human Interferon 2b Tablets
3 Major Manufacturers of Recombinant Human Interferon 2b in China, 2013-2017
3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Interferon 2b
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Huaxin High Biotechnology Inc.
3.3 Zhaoke Pharmaceutical (Hefei) Co. Ltd.
3.4 Schering-Plough
3.5 Beijing Kawin Technology Share-Holding Co., Ltd.
3.6 Tianjin Sinobioway Biomedicine Co., Ltd.
4 Prices of Recombinant Human Interferon 2b in China, 2017-2018
4.1 Shanghai Huaxin High Biotechnology Inc. (Xinhuanuo)
4.2 Zhaoke Pharmaceutical (Hefei) Co. Ltd. (Yallaferon)
4.3 Schering-Plough (Intron A)
4.4 Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Yisheng)
4.5 Tianjin Sinobioway Biomedicine Co., Ltd. (Alfaron)
5 Prospect of China's Recombinant Human Interferon 2b Market, 2018-2022
5.1 Major Factors Influencing Development of Recombinant Human Interferon 2b in China
5.2 Forecast on Market Size of Recombinant Human Interferon 2b in China
5.3 Forecast on Market Trend of Recombinant Human Interferon 2b in China
For more information about this report visit https://www.researchandmarkets.com/research/pnxjld/china_recombinant?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:SOURCE Research and Markets
